SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Lupus
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Yazdany, J
Right arrow Articles by Davis, J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yazdany, J
Right arrow Articles by Davis, J
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

The role of CD40 ligand in systemic lupus erythematosus

J Yazdany

Division of Rheumatology, University of California San Francisco, San Francisco, USA

J Davis

Division of Rheumatology, University of California San Francisco, San Francisco, USA, jdavis{at}medicine.ucsf.edu

CD40 ligand (CD40L, also known as CD154 or gp39) is a member of the tumor necrosis superfamily of transmembrane proteins. The interaction of CD40L on activated T cells with its receptor, CD40 on B cells, is necessary for normal immune function, including B cell differentiation, germinal center formation, and antibody isotype switching. Abnormal expressionof CD40L in patients with systemic lupus erythematosus (SLE) may contribute to autoantibody production and disease pathogenesis. Although murine models of monoclonal antibodies directed against CD40L initially showed promise, human trials either have failed to demonstrate efficacy or have been associated with adverse events. This review will summarize in vitro and murine model data and human clinical trials involving anti-CD40L monoclonal antibody.

Key Words: CD 154 • CD40 ligand • gp 39 • review • systemic lupus erythematosus

Lupus, Vol. 13, No. 5, 377-380 (2004)
DOI: 10.1191/0961203304lu1030oa
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Ann Rheum DisHome page
C B Driver, M Ishimori, and M H Weisman
The B cell in systemic lupus erythaematosus: a rational target for more effective therapy
Ann Rheum Dis, October 1, 2008; 67(10): 1374 - 1381.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
R. Puliaev, I. Puliaeva, L. A. Welniak, A. E. Ryan, M. Haas, W. J. Murphy, and C. S. Via
CTL-Promoting Effects of CD40 Stimulation Outweigh B Cell-Stimulatory Effects Resulting in B Cell Elimination and Disease Improvement in a Murine Model of Lupus
J. Immunol., July 1, 2008; 181(1): 47 - 61.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. A. Crist, D. L. Sprague, and T. L. Ratliff
Nuclear factor of activated T cells (NFAT) mediates CD154 expression in megakaryocytes
Blood, April 1, 2008; 111(7): 3553 - 3561.
[Abstract] [Full Text] [PDF]


Advertisement